HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini
A Multi-site, Open-label Non-inferiority Trial to Assess Immunogenicity of Two Doses of the Nonavalent Human Papillomavirus (HPV) Vaccine Among Children, Adolescents and Young Adults (9-26 Years) Living With HIV vs Three Doses of Nonavalent HPV Vaccine Among HIV Uninfected Young Women (15-26 Years) in Eswatini
Sponsor: Columbia University
A PHASE4 clinical study on HPV Infection and HPV Vaccine, this trial is completed. The trial is conducted by Columbia University and has accumulated 12 data snapshots since 2022. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Dec 2024 — Sep 2025 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE4
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE4
▶ Show 7 earlier versions
-
Mar 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE4
-
Oct 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE4
-
Jun 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jun 2022 — Jun 2023 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Apr 2022 — Jun 2022 [monthly]
Not Yet Recruiting PHASE4
-
Nov 2021 — Apr 2022 [monthly]
Not Yet Recruiting PHASE4
-
Sep 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Columbia University
- Jhpiego
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .